European Heart Journal Advance Access published online on February 16, 2005
European Heart Journal, doi:10.1093/eurheartj/ehi139
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Division of Cardiology, School of Medicine, Saint Louis University, St Louis, MO, USA
* To whom correspondence should be addressed. Aims To evaluate clinical outcomes associated with the combined use of clopidogrel and statins vs. clopidogrel alone on a background of aspirin therapy in patients with the spectrum of acute coronary syndromes (ACS). Methods and results Utilizing data from the Global Registry of Acute Coronary Events, we studied 15 693 patients admitted with non-ST-segment elevation myocardial infarction (MI) or unstable angina, dividing them according to discharge medications: aspirin alone (group I); aspirin + clopidogrel (group II); aspirin + statin (group III); aspirin + clopidogrel + statin (group IV). Among the groups of patients in whom clopidogrel was used (groups II and IV), group II patients were older, more likely to have prior MI, but less likely to have a history of prior revascularization. In-hospital cardiac catheterization and revascularization rates were similar between groups II and IV. Importantly, Kaplan-Meier analysis showed that the 6 month mortality rate was lower in group IV (log-rank test 22.8, P < 0.0001). The hazard ratio for the 6 month mortality rate was adjusted using the Cox proportional hazard model for confounding variables and for propensity score, and the 6 month mortality rate for patients in group IV remained lower compared with those in group II [0.59 (0.41-0.86), P < 0.0001]. Conclusion Our data suggest that the combination of clopidogrel with a statin has synergistic effects on the clinical outcomes of patients with non-ST-segment elevation ACS.
Clinical research
Impact of combined pharmacologic treatment with clopidogrel and a statin on outcomes of patients with non-ST-segment elevation acute coronary syndromes: perspectives from a large multinational registry
2 Division of Cardiovascular Medicine, University of Massachusetts Medical School, Worcester, MA, USA
3 Center for Outcomes Research, University of Massachusetts Medical School, Worcester, MA, USA
4 University of Perugia, Ospedale Silvestrini, Perugia, Italy
5 Division of Cardiology, The University of Michigan Cardiovascular Center, Ann Arbor, MI, USA
6 Duke Clinical Research Institute, Durham, NC, USA
Rajendra H. Mehta, E-mail: mehta007{at}dcri.duke.edu
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. W. Hamm, H. Möllmann, J.-P. Bassand, and F. van de Werf CHAPTER 16 Acute Coronary Syndromes ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Bhindi, O. Ormerod, J. Newton, A.P. Banning, and L. Testa Interaction between statins and clopidogrel: is there anything clinically relevant? QJM, December 1, 2008; 101(12): 915 - 925. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Patrono, C. Baigent, J. Hirsh, and G. Roth Antiplatelet Drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 199S - 233S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Angiolillo and F. Alfonso Clopidogrel Statin Interaction: Myth or Reality? J. Am. Coll. Cardiol., July 24, 2007; 50(4): 296 - 298. [Full Text] [PDF]
|
|
|
|
 |
|
 Authors/Task Force Members, J.-P. Bassand, C. W. Hamm, D. Ardissino, E. Boersma, A. Budaj, F. Fernandez-Aviles, K. A.A. Fox, D. Hasdai, E. M. Ohman, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology Eur. Heart J., July 1, 2007; 28(13): 1598 - 1660. [Full Text] [PDF]
|
|
|
|
 |
|
 W. S. Aronow Use of Antiplatelet Drugs in Secondary Prevention in Older Persons With Atherothrombotic Disease J. Gerontol. A Biol. Sci. Med. Sci., May 1, 2007; 62(5): 518 - 524. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-P. Bassand Drug interactions in the setting of acute coronary syndromes and dual anti-platelet therapy Eur. Heart J. Suppl., October 1, 2006; 8(suppl_G): G35 - G37. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. P. Giugliano and E. Braunwald The Year in Non-ST-Segment Elevation Acute Coronary Syndromes J. Am. Coll. Cardiol., July 18, 2006; 48(2): 386 - 395. [Full Text] [PDF]
|
|
|
|
|
|
Z. Almsherqi, C. Mclachlan, P. J. Mossop, and Y. Deng Combined pharmacologic treatment with clopidogrel and statin for patients with acute coronary syndrome: is there a survival advantage? Eur. Heart J., September 2, 2005; 26(18): 1932 - 1932. [Full Text] [PDF]
|
|
|
|
|
|
M. J. Lim, on behalf of the GRACE Investigators, and R. H. Mehta Combined pharmacological treatment with clopidogrel and statin for patients with acute coronary syndrome: is there a survival advantage?: reply Eur. Heart J., September 2, 2005; 26(18): 1933 - 1933. [Full Text] [PDF]
|
|